Fundraising Fox

Eyconis

Redwood City, US · Founded 2023 · Delaware corporation · 49 employees on LinkedIn · 4 known investors

Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform. The company aims to reduce treatment burden for patients by extending the duration between required injections while improving disease control and visual outcomes.

BiotechDigital HealthMedical Devices

Founders & leadership

EC
Emmett CunninghamExecutive
MB
Mark BachledainExecutive
RVRobert Vitti
Robert VittiExecutive
OSOliver Stauch
Oliver StauchinExecutive
OB
Oliver Boris StauchNamed on SEC filing
CW
Conrad WangNamed on SEC filing

Board

DEDan Estes
Dan Estesin𝕏Board directorGeneral Partner at Frazier Life Sciences
ACAnna Chen
Anna CheninBoard MemberPartner at Frazier Life Sciences
JM
Jan Moller MikkelsenBoard director
DEDaniel Estes
Daniel Estesin𝕏Board directorGeneral Partner at Frazier Life Sciences
GEGordon Empey
Gordon EmpeyinBoard directorCOO, Partner and General Counsel at Frazier Life Sciences
YYYvonne Yamanaka
Yvonne YamanakainBoard directorPartner at venBio Partners

Investors · 4

Frazier Life Sciences✓ verifiedPalo Alto
HealthQuest Capital✓ verifiedRedwood City
venBio Partners✓ verifiedSan Francisco
venBio Global StrategicreportedSan Francisco

Reported raises · per SEC filings

Form D private placements

$85.3M disclosed across 2 rounds · 2024–2025

▶$25MraisedOct 2025 · 7 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Conrad WangDirector
  • Yvonne YamanakaDirector
  • Emmett CunninghamExecutive Officer, Director
  • Mark BachledaExecutive Officer, Director
  • Robert VittiExecutive Officer
  • Dan EstesDirector
  • Anna ChenDirector
  • Oliver StauchExecutive Officer
  • Jan Moller MikkelsenDirector
Offering amount
$89.8M
Amount sold
$25M
First sale
Oct 2025
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$60.3MraisedFeb 2024 · 7 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Daniel EstesExecutive Officer, Director, Promoter
  • Oliver Boris StauchExecutive Officer
  • Emmett CunninghamExecutive Officer, Director, Promoter
  • Jan Moller MikkelsenDirector
  • Gordon EmpeyExecutive Officer, Promoter
  • Conrad WangDirector
  • Yvonne YamanakaDirector
  • Anna ChenExecutive Officer, Director, Promoter
Offering amount
$150M
Amount sold
$60.3M
First sale
Jan 2024
Incorporated
Corporation, Delaware, 2023
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Ois31 shared keywordsOIS is a conference and community, active since 2009, focused on eye care and ophthalmology innovation, connecting startups, strategics, investors, and clinicians. It provides curated programming, networking, and access to new technologies in the ophthalmology industry.
Bioworld20 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Eyconis for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Eyconis do?
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform. The company aims to reduce treatment burden for patients by extending the duration between required injections while improving disease control and visual outcomes.
Who are Eyconis's investors?
Eyconis's investors include Frazier Life Sciences, HealthQuest Capital, venBio Partners, venBio Global Strategic.
How much funding has Eyconis raised?
Eyconis has disclosed $85.3M raised across 2 rounds.
Where is Eyconis headquartered?
Eyconis is headquartered in Redwood City, US.